Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

[New anticoagulants: stop or more?].

Laroche JP.

J Mal Vasc. 2014 Feb;39(1):1-3. doi: 10.1016/j.jmv.2013.12.004. French. No abstract available.

PMID:
24412008
2.

The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.

Kowey PR, Naccarelli GV.

Am J Med. 2012 Aug;125(8):732. doi: 10.1016/j.amjmed.2011.10.035. No abstract available.

PMID:
22608987
3.

Place of dabigatran in contemporary pharmacotherapy.

Gums JG.

Pharmacotherapy. 2011 Apr;31(4):335-7. doi: 10.1592/phco.31.4.335. No abstract available.

PMID:
21449622
4.

[New anticoagulants: "efficacy and safety" or "efficacy or safety"].

Pernod G.

J Mal Vasc. 2011 Dec;36(6):337-8. doi: 10.1016/j.jmv.2011.07.073. French. No abstract available.

PMID:
21907510
5.

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.

Beasley BN, Unger EF, Temple R.

N Engl J Med. 2011 May 12;364(19):1788-90. doi: 10.1056/NEJMp1103050. No abstract available.

6.

Dabigatran in patients with nonvalvular atrial fibrillation.

Gage L.

J Am Coll Cardiol. 2011 Jul 26;58(5):551; author reply 551. doi: 10.1016/j.jacc.2011.04.016. No abstract available.

7.

[Novel oral anticoagulants and atrial fibrillation in the elderly].

Hanon O.

Geriatr Psychol Neuropsychiatr Vieil. 2013 Dec;11(1 Suppl):34-40. doi: 10.1684/pnv.2013.0444. Review. French.

PMID:
24463062
8.

Dabigatran (Pradaxa).

Comin J, Kallmes DF.

AJNR Am J Neuroradiol. 2012 Mar;33(3):426-8. doi: 10.3174/ajnr.A3000.

9.

[Dosage of the new oral anticoagulants is essential for frequency of adverse events].

Kræmmer Nielsen H.

Ugeskr Laeger. 2013 Feb 4;175(6):331. Danish. No abstract available.

PMID:
23402233
10.

[Clinical management of the new anticoagulants].

Zapata Wainberg G, Ximénez-Carrillo Rico A, Vivancos Mora J.

Neurologia. 2012 Mar;27 Suppl 1:33-8. doi: 10.1016/S0213-4853(12)70006-3. Review. Spanish.

11.

[Differential therapy with the new anticoagulants, 5].

Stiefelhagen P.

MMW Fortschr Med. 2013 May 16;155(9):20. German. No abstract available.

PMID:
23951642
12.

Next generation anticoagulants may push warfarin to the wayside.

Kirsch B.

Manag Care. 2011 Feb;20(2):33-6. No abstract available.

13.

Dabigatran: how the drug company withheld important analyses.

Cohen D.

BMJ. 2014 Jul 23;349:g4670. doi: 10.1136/bmj.g4670. No abstract available.

14.

[Gastrointestinal bleeding under treatment with new oral anticoagulants].

Konturek P, Hess T.

MMW Fortschr Med. 2014 Feb 6;156(2):50-2. Review. German. No abstract available.

PMID:
24934056
15.

New oral anticoagulants and risks in ENT.

Hollis S.

Clin Otolaryngol. 2013 Aug;38(4):355-7. doi: 10.1111/coa.12148. No abstract available.

PMID:
23957550
16.

Concerns over data in key dabigatran trial.

Cohen D.

BMJ. 2014 Jul 23;349:g4747. doi: 10.1136/bmj.g4747. No abstract available.

PMID:
25055831
17.

[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

Dumont B, Faille D, Ajzenberg N.

Med Sci (Paris). 2011 May;27(5):493-500. doi: 10.1051/medsci/2011275014. Review. French.

18.

Avoiding adverse events with dabigatran by careful selection of eligible patients.

Baker RI, Harper P, McLintock C.

Med J Aust. 2012 Apr 16;196(7):431-2. No abstract available.

PMID:
22509863
19.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
20.

[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].

[No authors listed]

MMW Fortschr Med. 2012 Jan 19;154(1):20. German. No abstract available.

PMID:
22641998

Supplemental Content

Support Center